‘Arcturus,’ a highly transmissible COVID variant eyed by the WHO, appears to have a new symptom. Here's what you need to know
A new strain, dubbed Arcturus (XBB 1.16), is becoming prominent in India, and “an infantile phenotype seems [to be] emerging”. Pediatric cases are on the rise with a new symptom: conjunctivitis, more commonly known as “pink eye”.
XBB.1.16 is a recombinant of two descendants of so-called “stealth Omicron” BA.2. A preprint study updated Sunday from scientists at the University of Tokyo suggests that it spreads about 1.17 to 1.27 times more efficiently than relatives XBB.1 and XBB.1.5, also known as “Kraken,” which currently dominates U.S. cases.
XBB.1.16’s increased ability to outpace other variants suggest that it “will spread worldwide in the near future,” researchers wrote, adding that the variant is “robustly resistant” to antibodies from a variety of COVID variants, including “stealth Omicron” BA.2 and BA.5, which surged globally last summer.
Your vaccine, now woefully outdated especially if you did not receive the bivalent booster, will only marginally protect you. Even if you caught Covid within the last 6 months, your antibodies are negligible.
If you know anyone who has recently returned from India or any neighboring countries, encourage them to mask and isolate. If you or your children are experiencing mild cold/allergy symptoms, especially red, itchy, watery, and/or sticky eyes, please wear a mask, isolate if you can, and test for Covid. “Adenovirus, which has symptoms similar to COVID, can also result in conjunctivitis. Adenovirus and COVID are impossible to distinguish from each other without testing.”
At the time of this posting, it looks like XBB 1.16/Arcturus has already made it to the US, UK, most of Europe, and even Australia and New Zealand. The lineage is being tracked here.
| Wednesday 5/3 |






